Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO-1162 Phase 3 study A placebo-controlled multicentre double-blind randomized parallel-group study in patients with chronic heart failure (J-SHIFT study)

Next Previous
Trial Profile

ONO-1162 Phase 3 study A placebo-controlled multicentre double-blind randomized parallel-group study in patients with chronic heart failure (J-SHIFT study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms J-SHIFT
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 05 Aug 2022 Status changed from active, no longer recruiting to completed.
    • 27 Feb 2021 Results of meta-analysis of 6 studies, published in the Clinical Cardiology.
    • 20 Sep 2019 According to an Ono pharmaceutical media release, based on the data from SHIFT and J-SHIFT studies, In December 2018, the company has received the manufacturing and marketing approval of Corolan (Ivabradine) in Japan, for the treatment of patients with chronic heart failure with resting heart rate greater that or equal to 75 beats per minute in sinus rhythm.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top